Los Angeles Capital Management LLC Has $1.45 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Los Angeles Capital Management LLC decreased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 60.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,561 shares of the medical instruments supplier’s stock after selling 8,376 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Insulet were worth $1,452,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Allianz Asset Management GmbH increased its stake in shares of Insulet by 27.7% during the 4th quarter. Allianz Asset Management GmbH now owns 113,921 shares of the medical instruments supplier’s stock worth $29,741,000 after purchasing an additional 24,734 shares during the last quarter. ING Groep NV acquired a new position in shares of Insulet during the 4th quarter worth $556,000. Handelsbanken Fonder AB increased its stake in shares of Insulet by 9.9% during the 4th quarter. Handelsbanken Fonder AB now owns 18,916 shares of the medical instruments supplier’s stock worth $4,938,000 after purchasing an additional 1,700 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of Insulet by 30.5% during the 4th quarter. Private Advisor Group LLC now owns 9,642 shares of the medical instruments supplier’s stock worth $2,517,000 after purchasing an additional 2,255 shares during the last quarter. Finally, Alberta Investment Management Corp boosted its holdings in shares of Insulet by 57.6% during the 4th quarter. Alberta Investment Management Corp now owns 3,400 shares of the medical instruments supplier’s stock worth $888,000 after buying an additional 1,242 shares during the period.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

PODD has been the subject of several recent analyst reports. Citigroup upped their price objective on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. StockNews.com raised shares of Insulet from a “hold” rating to a “buy” rating in a report on Monday, February 24th. Raymond James reaffirmed an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $289.06.

Insulet Price Performance

NASDAQ:PODD opened at $272.27 on Friday. The company has a 50-day moving average of $274.01 and a 200-day moving average of $249.91. The company has a market capitalization of $19.10 billion, a price-to-earnings ratio of 47.02, a PEG ratio of 3.62 and a beta of 1.23. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.